ZA200802977B - Bicyclic derivatives as modulators of voltage gated ion channels - Google Patents

Bicyclic derivatives as modulators of voltage gated ion channels

Info

Publication number
ZA200802977B
ZA200802977B ZA200802977A ZA200802977A ZA200802977B ZA 200802977 B ZA200802977 B ZA 200802977B ZA 200802977 A ZA200802977 A ZA 200802977A ZA 200802977 A ZA200802977 A ZA 200802977A ZA 200802977 B ZA200802977 B ZA 200802977B
Authority
ZA
South Africa
Prior art keywords
modulators
ion channels
gated ion
voltage gated
bicyclic derivatives
Prior art date
Application number
ZA200802977A
Other languages
English (en)
Inventor
Nieubert Timothy
Zimmerman Nicole
Kawatkar Artis
Martinborough Esther
Termin Andreas
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of ZA200802977B publication Critical patent/ZA200802977B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/50—Nitrogen atoms bound to hetero atoms
    • C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA200802977A 2005-09-09 2006-09-08 Bicyclic derivatives as modulators of voltage gated ion channels ZA200802977B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US71598005P 2005-09-09 2005-09-09

Publications (1)

Publication Number Publication Date
ZA200802977B true ZA200802977B (en) 2009-08-26

Family

ID=37686027

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200802977A ZA200802977B (en) 2005-09-09 2006-09-08 Bicyclic derivatives as modulators of voltage gated ion channels

Country Status (14)

Country Link
US (4) US7855220B2 (https=)
EP (1) EP1928871A2 (https=)
JP (1) JP2009507851A (https=)
KR (1) KR20080044910A (https=)
CN (1) CN101300253B (https=)
AU (1) AU2006287480B2 (https=)
CA (1) CA2622076A1 (https=)
IL (1) IL190017A0 (https=)
MX (1) MX2008003337A (https=)
NO (1) NO20081725L (https=)
NZ (1) NZ567132A (https=)
RU (1) RU2008113836A (https=)
WO (1) WO2007030618A2 (https=)
ZA (1) ZA200802977B (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7491827B2 (en) * 2002-12-23 2009-02-17 Millennium Pharmaceuticals, Inc. Aryl sulfonamides useful as inhibitors of chemokine receptor activity
US7615563B2 (en) * 2003-08-08 2009-11-10 Gonzalez Iii Jesus E Compositions useful as inhibitors of voltage-gated sodium channels
KR20080015102A (ko) * 2005-05-10 2008-02-18 버텍스 파마슈티칼스 인코포레이티드 이온 채널 조절인자로서의 바이사이클릭 유도체
ATE527251T1 (de) * 2005-05-16 2011-10-15 Vertex Pharma Bicyclische derivate als modulatoren von ionenkanälen
MX2008003337A (es) * 2005-09-09 2008-09-26 Vertex Pharma Derivados biciclicos como modulares de canales ionicos regulados por voltaje.
EP1948597A1 (en) * 2005-10-21 2008-07-30 Vertex Pharmaceuticals Incorporated Derivatives for modulation of ion channels
NZ593074A (en) 2005-12-21 2012-04-27 Vertex Pharma sulfonamide-pyrrolidone derivatives as Modulators of Ion Channels
AU2008256937A1 (en) 2007-05-25 2008-12-04 Vertex Pharmaceuticals Incorporated Ion channel modulators and methods of use
US7994174B2 (en) * 2007-09-19 2011-08-09 Vertex Pharmaceuticals Incorporated Pyridyl sulfonamides as modulators of ion channels
CN101910166A (zh) * 2007-11-13 2010-12-08 沃泰克斯药物股份有限公司 用作钠离子通道调节剂的杂环衍生物
EP2231655B1 (en) 2007-11-13 2011-08-31 Vertex Pharmaceuticals Incorporated 4(-3-(-2-(phenyl)morpholino)-2-oxopyrrolidin-1-yl)-n-(thiazol-2-yl)benzenesulfonamide derivatives and related compounds as modulators of ion channels for the treatment of pain
WO2009133641A1 (ja) * 2008-04-30 2009-11-05 シャープ株式会社 照明装置、及び表示装置
RU2011103451A (ru) * 2008-07-01 2012-08-10 Вертекс Фармасьютикалз Инкорпорейтед (Us) Гетероциклические производные в качестве модуляторов ионных каналов
BRPI0913879A2 (pt) * 2008-07-02 2019-09-24 Hoffmann La Roche fenilpirazinonas como inibidores de quinase
EP2323482A4 (en) * 2008-08-06 2011-08-17 Merck & Co Inc SUBSTITUTED DIHYDROISOCHINOLINONE AND ISOCHINOLINDION DERIVATIVES AS CALCIUM CHANNEL BLOCKERS
KR102295748B1 (ko) 2013-01-31 2021-09-01 버텍스 파마슈티칼스 인코포레이티드 나트륨 채널의 조절제로서의 피리돈 아미드
AU2019302534B2 (en) 2018-07-09 2024-10-03 Lieber Institute, Inc. Pyridazine compounds for inhibiting NaV1.8
AU2019301628C1 (en) 2018-07-09 2025-02-06 Lieber Institute, Inc. Pyridine carboxamide compounds for inhibiting NaV1.8
CN114901642B (zh) * 2019-12-30 2024-02-23 武汉朗来科技发展有限公司 一种稠环化合物及其应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378715A (en) * 1992-02-24 1995-01-03 Bristol-Myers Squibb Co. Sulfonamide endothelin antagonists
TWI234557B (en) 1999-05-26 2005-06-21 Telik Inc Novel naphthalene ureas as glucose uptake enhancers
JP2003055209A (ja) * 2001-07-31 2003-02-26 Bayer Ag フェニルナフチル尿素誘導体
WO2003097586A1 (en) * 2002-05-17 2003-11-27 Janssen Pharmaceutica N.V. Aminotetralin-derived urea modulators of vanilloid vr1 receptor
US7491827B2 (en) * 2002-12-23 2009-02-17 Millennium Pharmaceuticals, Inc. Aryl sulfonamides useful as inhibitors of chemokine receptor activity
US7615563B2 (en) * 2003-08-08 2009-11-10 Gonzalez Iii Jesus E Compositions useful as inhibitors of voltage-gated sodium channels
US8202861B2 (en) * 2003-08-08 2012-06-19 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of voltage-gated sodium channels
KR20080015102A (ko) * 2005-05-10 2008-02-18 버텍스 파마슈티칼스 인코포레이티드 이온 채널 조절인자로서의 바이사이클릭 유도체
ATE527251T1 (de) * 2005-05-16 2011-10-15 Vertex Pharma Bicyclische derivate als modulatoren von ionenkanälen
MX2007015726A (es) * 2005-06-09 2008-03-04 Vertex Pharma Derivados de indano como moduladores de canales ionicos.
MX2008003337A (es) * 2005-09-09 2008-09-26 Vertex Pharma Derivados biciclicos como modulares de canales ionicos regulados por voltaje.
RU2008118350A (ru) 2005-10-12 2009-11-20 Вертекс Фармасьютикалз Инкорпорейтед (Us) Бифенильные производные в качестве модуляторов потенциалзависимых ионных каналов
EP1948597A1 (en) * 2005-10-21 2008-07-30 Vertex Pharmaceuticals Incorporated Derivatives for modulation of ion channels
NZ593074A (en) * 2005-12-21 2012-04-27 Vertex Pharma sulfonamide-pyrrolidone derivatives as Modulators of Ion Channels
US8293450B2 (en) * 2006-11-28 2012-10-23 Hewlett-Packard Development Company, L.P. Laser imaging coating and methods for imaging
AU2008256937A1 (en) * 2007-05-25 2008-12-04 Vertex Pharmaceuticals Incorporated Ion channel modulators and methods of use
US7994174B2 (en) * 2007-09-19 2011-08-09 Vertex Pharmaceuticals Incorporated Pyridyl sulfonamides as modulators of ion channels
CN101910166A (zh) 2007-11-13 2010-12-08 沃泰克斯药物股份有限公司 用作钠离子通道调节剂的杂环衍生物
EP2231655B1 (en) * 2007-11-13 2011-08-31 Vertex Pharmaceuticals Incorporated 4(-3-(-2-(phenyl)morpholino)-2-oxopyrrolidin-1-yl)-n-(thiazol-2-yl)benzenesulfonamide derivatives and related compounds as modulators of ion channels for the treatment of pain
RU2011103451A (ru) * 2008-07-01 2012-08-10 Вертекс Фармасьютикалз Инкорпорейтед (Us) Гетероциклические производные в качестве модуляторов ионных каналов

Also Published As

Publication number Publication date
KR20080044910A (ko) 2008-05-21
US20130131109A1 (en) 2013-05-23
RU2008113836A (ru) 2009-10-20
NZ567132A (en) 2011-12-22
AU2006287480A1 (en) 2007-03-15
IL190017A0 (en) 2008-08-07
JP2009507851A (ja) 2009-02-26
US8492403B2 (en) 2013-07-23
AU2006287480B2 (en) 2012-07-05
NO20081725L (no) 2008-06-09
US20110112156A1 (en) 2011-05-12
MX2008003337A (es) 2008-09-26
EP1928871A2 (en) 2008-06-11
CN101300253A (zh) 2008-11-05
WO2007030618A2 (en) 2007-03-15
US20120308606A1 (en) 2012-12-06
CA2622076A1 (en) 2007-03-15
US8357702B2 (en) 2013-01-22
CN101300253B (zh) 2012-08-22
US8236829B2 (en) 2012-08-07
US7855220B2 (en) 2010-12-21
WO2007030618A3 (en) 2007-05-31
AU2006287480A8 (en) 2012-02-02
US20070203130A1 (en) 2007-08-30

Similar Documents

Publication Publication Date Title
ZA200709961B (en) Bicyclic derivatives as modulators of ion channels
ZA200805338B (en) Heterocyclic derivatives as modulators of ion channels
ZA200802977B (en) Bicyclic derivatives as modulators of voltage gated ion channels
ZA201009128B (en) Heterocyclic derivatives as modulators of ion channels
ZA200800191B (en) Indane derivatives as modulators of ion channels
NO20054546D0 (no) Kinazoliner nyttige som modulatorer av ionekanaler
IL192214A0 (en) Compositions and methods for modulating gated ion channels
IL194311A (en) Pyrolopyridine compounds as HIF modulators
IL197958A0 (en) Bicyclic triazoles as protein kinase modulators
PL2081937T3 (pl) Triazolopirydazynowe modulatory kinaz białkowych
IL190544A (en) Quaternary history of alpha-aminocarboxamide as modulators of voltage-activated calcium channels
IL185972A0 (en) Process for the preparation of opioid modulators
ZA200902170B (en) Bicyclic triazoles as protein kinase modulators
ZA200805241B (en) Heterocyclic GABAB modulators
ZA200804043B (en) Quinazolines useful as modulators of voltage gates ion channels
GB2424881B (en) Halophenyl derivatives of bisalkylfluorene
ZA200710560B (en) Resolution of enantiomeric mixtures of ß-lactams
PL1838350T3 (pl) Modulatory aktywności ubikwitynazy itch
EP1945029A4 (en) ION CHANNEL INHIBITORS
GB0610652D0 (en) An improved integrating structure of switch plates
HK1119693A (en) Quaternary alpha-aminocarboxamide derivatives as modulators of voltage-gated sodium channels
AU2005901180A0 (en) Patent For The Fountain of youth
HK1132508A (en) Bicyclic triazoles as protein kinase modulators
HK1128690A (en) Bicyclic tetrahydropyrrole compounds
HK1128470A (en) Bicyclic tetrahydropyrrole compounds